0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Efficacy and Tolerability of Lovastatin in 3390 Women with Moderate Hypercholesterolemia

Reagan H. Bradford, MD, PhD; Maria Downton, MS; Athanassios N. Chremos, MD; Alexandra Langendorfer, MS; Sandra Stinnett, MS; David T. Nash, MD; Geraldine Mantell, MD; and Charles L. Shear, DrPH
[+] Article and Author Information

From Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma; ClinTrials, Inc., Research Triangle Park, North Carolina; Merck Research Laboratories, West Point, PA; State University of New York Health Science Center at Syracuse, New York. Requests for Reprints: Reagan H. Bradford, MD, PhD, Oklahoma Medical Research Foundation, 825 Northeast 13th Street, Oklahoma City, OK 73104. Acknowledgments: The authors thank the investigators (listed in reference 7) who made this study possible. They also thank Patience Vanderbush for editorial assistance. Grant Support: In part by grants to clinical sites from ClinTrials Inc., Research Triangle Park, North Carolina, which was responsible for the execution of this study sponsored by Merck & Co., Inc., Rahway, New Jersey.


Copyright 2004 by the American College of Physicians


Ann Intern Med. 1993;118(11):850-855. doi:10.7326/0003-4819-118-11-199306010-00004
Text Size: A A A

Objective: To evaluate the efficacy and safety of lovastatin in women with moderate hypercholesterolemia.

Design: The Expanded Clinical Evaluation of Lovastatin (EXCEL) Study, a multicenter, double-blind, diet- and placebo-controlled trial, in which participants were randomly assigned to receive placebo or lovastatin at doses of 20 or 40 mg once daily, or 20 or 40 mg twice daily for 48 weeks.

Setting: Ambulatory patients recruited by 362 participating centers throughout the United States.

Patients: Women (n = 3390) from the total cohort of 8245 volunteers.

Measurements: Plasma total, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol, and triglycerides; and laboratory and clinical evidence of adverse events monitored periodically throughout the study.

Results: Among women, lovastatin (20 to 80 mg/d) produced sustained (12- to 48-week), dose-related changes (P < 0.001): decreases in LDL cholesterol (24% to 40%) and triglycerides (9% to 18%), and increases in HDL cholesterol (6.7% to 8.6%). Depending on the dose, from 82% to 95% of lovastatin-treated women achieved the National Cholesterol Education Program goal of LDL cholesterol levels less than 4.14 mmol/L (160 mg/dL), and 40% to 87% achieved the goal of 3.36 mmol/L (130 mg/dL). Successive transaminase elevations greater than three times the upper limit of normal occurred in 0.1% of women and were dose dependent above the 20-mg dose. Myopathy, defined as muscle symptoms with creatine kinase elevations greater than 10 times the upper limit of normal, was rare and associated with the highest recommended daily dose of lovastatin (80 mg). Estrogen-replacement therapy appeared to have no effect on either the efficacy or safety profile of lovastatin.

Conclusion: Lovastatin is highly effective and generally well tolerated as therapy for primary hypercholesterolemia in women.

Figures

Grahic Jump Location
Figure 1.
Percentage of women achieving National Cholesterol Education Program target levels for low-density cholesterol at week 48.

The white bars at left indicate those women without coronary heart disease (CHD) and with fewer than two CHD risk factors (goal-low-density lipoprotein less than 4.14 mmol/L). The black bars at the right indicate those women with coronary heart disease or with two or more CHD risk factors (goal: low-density lipoprotein less than 3.36 mmol/L).

Grahic Jump Location

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
PubMed Articles

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)